Link to this page
Biological and Environmental Research Ontology
Last uploaded:
December 23, 2022
| Id | http://purl.obolibrary.org/obo/NCIT_C2015
http://purl.obolibrary.org/obo/NCIT_C2015
|
|---|---|
| Preferred Name | Abarelix |
| Definitions |
A synthetic decapeptide and antagonist of naturally occurring gonadotropin-releasing hormone (GnRH). Abarelix directly and competitively binds to and blocks the gonadotropin releasing hormone receptor in the anterior pituitary gland, thereby inhibiting the secretion and release of luteinizing hormone (LH) and follicle stimulating hormone (FSH). In males, the inhibition of LH secretion prevents the release of testosterone. As a result, this may relieve symptoms associated with prostate hypertrophy or prostate cancer, since testosterone is required to sustain prostate growth.
|
| Type | http://www.w3.org/2002/07/owl#Class |
All Properties
| definition | A synthetic decapeptide and antagonist of naturally occurring gonadotropin-releasing hormone (GnRH). Abarelix directly and competitively binds to and blocks the gonadotropin releasing hormone receptor in the anterior pituitary gland, thereby inhibiting the secretion and release of luteinizing hormone (LH) and follicle stimulating hormone (FSH). In males, the inhibition of LH secretion prevents the release of testosterone. As a result, this may relieve symptoms associated with prostate hypertrophy or prostate cancer, since testosterone is required to sustain prostate growth. |
|---|---|
| prefLabel | Abarelix
|
| label | Abarelix
|
| CHEBI_ID | CHEBI:337298
|
| PDQ_Closed_Trial_Search_ID | 415570
|
| code | C2015
|
| Has_Target | |
| prefixIRI | NCIT:C2015
|
| in_subset |
See more
See less
|
| Display_Name | Abarelix
|
| Preferred_Name | Abarelix
|
| FDA_UNII_Code | W486SJ5824
|
| Contributing_Source |
CTRP
FDA
|
| Chemical_Formula | C72H95ClN14O14
|
| Maps_To | Abarelix
|
| CAS_Registry | 183552-38-7
|
| NCI_Drug_Dictionary_ID | 415570
|
| Legacy Concept Name | Abarelix
|
| type | |
| ALT_DEFINITION | A drug used to reduce the amount of testosterone made in patients with advanced symptomatic prostate cancer for which no other treatment options are available. It belongs to the family of drugs called gonadotropin-releasing hormone (GnRH) antagonists.
|
| Is_Value_For_GDC_Property | |
| subClassOf | |
| PDQ_Open_Trial_Search_ID | 415570
|
| Accepted_Therapeutic_Use_For | Prostate Cancer
|
| Semantic_Type |
Amino Acid, Peptide, or Protein
Pharmacologic Substance
|
| UMLS_CUI | C1174732
|
| Delete | Subject | Author | Type | Created |
|---|---|---|---|---|
| No notes to display |